Investor Relations
Breakthrough Oxygenation
Investment Highlights
Innovative and cost-effective
technology for respiratory support
technology for respiratory support
Early elevation of oxygen saturation
levels to minimize the need for
mechanical ventilation
levels to minimize the need for
mechanical ventilation
Designed to be administered while
patients are awake and
breathing spontaneously
patients are awake and
breathing spontaneously
Aims to reduce
length of hospital stays
and costs
length of hospital stays
and costs
Total addressable market
of $20 billion
of $20 billion
Experienced and committed
management team
management team
Latest news and press releases
September 22, 2021
Inspira Technologies’ “Artificial Lung” To Acquire A Digital Edge: The Company Contracted GlobalLogic, A Hitachi Group Company, For Advanced Digital Product Engineering Services
SEC Filings
Research Coverage
Bank
Analyst
Phone
E-mail
Aegis Capital
Nathan Weinstein, CFA
646-502-2522
nweinstein@aegiscap.com
These reports are prepared by independent analysts. Inspira does not endorse or distribute such reports and takes no responsibility for the accuracy or completeness of the material contained in the reports. Please note that any opinions, estimates or forecasts regarding the company’s performance made by these analysts are theirs alone and do not represent opinions, forecasts, or predictions of Inspira Technologies.
